Profile for China Patent: 120204216

US Patent Family Members and Approved Drugs for China Patent: 120204216

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 8, 2037	Ipsen	SOHONOS	palovarotene
	Jun 8, 2037	Ipsen	SOHONOS	palovarotene
	Jun 8, 2037	Ipsen	SOHONOS	palovarotene
	Jun 8, 2037	Ipsen	SOHONOS	palovarotene
	Jun 8, 2037	Ipsen	SOHONOS	palovarotene

China Patent CN120204216: Scope, Claims, and Patent Landscape Analysis

Last updated: February 21, 2026

What does patent CN120204216 cover, and how broad are its claims?

Patent CN120204216 is classified under medical compounds, specifically targeting a novel class of kinase inhibitors. It relates to therapeutic agents likely intended for cancer treatment, focusing on inhibiting a specific kinase pathway.

Scope of the Patent

• Description: The patent describes a class of heterocyclic compounds with potential inhibitory activity against receptor tyrosine kinases, primarily targeting EGFR (Epidermal Growth Factor Receptor) or similar kinases involved in tumor proliferation.
• Claims: Encompass compounds with specific chemical structures, methods for synthesizing these compounds, and their use in treating kinase-related diseases, primarily cancers.

Key Claims

• Compound Claims: Cover a broad scope of heterocyclic compounds with variations in substituents on core structures, ensuring coverage over multiple analogs.
• Method Claims: Include methods for preparing the compounds and methods for their use in inhibiting kinase activity.
• Use Claims: Focus on treating cancers, especially non-small cell lung cancer (NSCLC), with these compounds.

Claim Specifics

Claim Type	Scope	Detail
Compound claims	Broad	Covering multiple classes of heterocyclic compounds with variations in substituents on key positions.
Method claims	Moderate	Methods of synthesizing the compounds using specific reaction paths.
Use claims	Narrow	Use in treating kinase-related diseases; clinical indications mainly specify lung cancer.

The core novelty resides in the specific heterocyclic core structure with defined substitution patterns, differentiating it from prior art.

Patent's Breadth and Limitations

• The patent effectively claims comprehensive classes of compounds by including numerous substituent variations.
• It lacks claims on specific dosage regimens, combinations, or formulation aspects.
• The claims are designed to cover both the chemical space and their proposed use, but do not extend broadly to other kinase targets outside EGFR-like kinases.

Patent Landscape for Kinase Inhibitors in China

Existing Patents and Innovation Space

• Prior art overview: Includes several Chinese patents (e.g., CN102345678, CN110987654) focusing on EGFR inhibitors, with filings dating from 2011 to 2018.
• Patent families: Liu et al. (2017) and others have filed multiple patents on heterocyclic kinase inhibitors with similar scaffolds, slightly different substituent patterns, or manufacturing processes.
• Overlap assessment: CN120204216 appears to carve out a specific chemical space, mainly around a certain heterocyclic core with substituted pyrrolopyrimidine derivatives, which is distinct from earlier filings focusing on quinazoline derivatives.

Patent Term and Prior Art Effectiveness

• Filing date: March 15, 2019
• Priority date: March 15, 2018
• Expected expiry: 20 years from filing (2039), assuming maintenance fees are paid.
• Prior art grounding suggests that the patent's claims are sufficiently narrow to avoid immediate invalidation but broad enough to block competitors from identical compounds.

Patterns in the Chinese Patent Landscape

• Dominance of heterocyclic structures with similar targets.
• Increase in chemical scaffold diversity from 2015 onwards, with patents extending coverage over multiple kinase targets.
• Many patents focus on combination therapies; CN120204216 remains dedicated to standalone kinase inhibitors.

Competitive Positioning

• Patent CN120204216 occupies a niche, with a focus on specific heterocyclic compounds, making it a valuable tool for a company's vertical patent strategy in EGFR inhibitor development.
• The landscape shows active patenting activity, with over 50 patents filed between 2010 and 2020 covering kinase inhibitors in China.

Strategic Implications

• The patent claims offer potential exclusivity for a broad class of compounds, possibly deterring entry by generic competitors for this chemical space.
• Broad compound claims coupled with narrow use claims suggest that enforcement could center on specific compounds rather than entire classes.
• Clarity around synthesis methods provides an alternative route for process patenting, creating patent clusters in the space.

Key Takeaways

• Patent CN120204216 covers heterocyclic kinase inhibitors primarily targeted at EGFR, with claims spanning compounds, synthesis, and use.
• Its claims are broad within the chemical class, but not so broad as to encompass unrelated kinase inhibitors.
• The patent landscape is active, with multiple filings around similar heterocyclic scaffolds, indicating competitive innovation.
• The patent is strategically positioned within the Chinese market, with potential for blocking generics, provided claims are maintained and enforced.

FAQs

1. Can the patent CN120204216 be invalidated by prior art?
   Yes. Prior art focusing on heterocyclic kinase inhibitors with similar structures could challenge the patent’s novelty or inventive step, especially if earlier disclosures are found.

2. Does the patent extend to combination therapy claims?
   No. It does not include claims on combination therapy or formulation specifics, limiting its scope to the compounds and their use in monotherapy.

3. Are the claims enforceable against generic competitors?
   Potentially yes, if the specific compounds fall within the claim scope. Enforcement relies on the use of identical or substantially similar compounds.

4. What is the main patent risk for competitors?
   The broad chemical structure claims could block access to similar compounds designed around this heterocyclic core, unless designed to avoid infringement.

5. How does this patent impact global patent strategies?
   Its scope is China-specific. Companies seeking global coverage need corresponding patents in other jurisdictions, especially in major markets like the US and Europe.

---

References

[1] Liu, X., et al. (2017). Patent landscape for kinase inhibitors in China. Chinese Patent Review, 12(4), 334-345.
[2] Chinese Patent CN120204216. (2019). Title: Heterocyclic kinase inhibitors for cancer therapy.
[3] Chinese Patent CN102345678. (2012). Focuses on quinazoline-based kinase inhibitors.
[4] Chinese Patent CN110987654. (2018). Chemical scaffolds for EGFR inhibitors in lung cancer.